WCLC

WCLC 2018 Toronto

Expert interviews at WCLC 2018

 

Herbert Loong on peculiarities of lung cancer research with a focus on phase I studies.

James Ho talks about novel diagnostic approaches, monitoring of lung cancer patients as well as the potential for the use of antioxidants in lung cancer.

Maximilian Hochmair on the future of combinations of immunotherapies with other drugs as well as his recommendations for treatment sequencing in ALK-positive and EGFR-positive lung cancer.

Vera Hirsh discusses the latest clinical achievements using EGFR-targeted therapy in patients with advanced NSCLC and the role of patient quality of life.

Virote Sriuranpong talks about new agents in the area of EGFR-targeted therapy as well as the results obtained with afatinib in a named patient program at Asian centers.


English

Mandarin

Japanese

Expert interviews at WCLC

IASLC 18th WCLC 2017, Yokohama
Prof. David Gandara discusses the latest progress in EGFR, ALK, and checkpoint inhibitor therapies for NSCLC.

IASLC 18th WCLC 2017, Yokohama
Prof. Keunchil Park discusses how lung cancer treatments have developed since the advent of chemotherapy, and how best to deliver optimal care to lung cancer patients worldwide, and specifically in South Korea and Japan.

IASLC 18th WCLC 2017, Yokohama
Prof. Ramaswamy Govindan discusses the importance of chemotherapy in today’s treatment landscape, and the importance of ethnic genomic differences in mutation rates in lung cancer.

IASLC 18th WCLC 2017, Yokohama
Prof. Paul A. Bunn discusses current and future treatment options in lung cancer.


WCLC 2016

English

Spanish

Japanese

Mandarin

Expert interviews at WCLC

Martin Schuler on the current state-of-play for EGFR diagnostic technologies

Johan Vansteenkiste discusses the practical considerations for immunotherapy

Robert Pirker on the hot topics in lung cancer research on the agenda at the IASLC 2017 WCLC congress

Fiona Blackhall on the importance of molecular diagnosis on the diagnosis and follow up of lung cancer

James Chih-Hsin Yang talks TKIs